R21TW012889
Project Grant
Overview
Grant Description
Building a collaborative research and training platform for HIV and rheumatic and musculoskeletal diseases in Uganda - project summary/abstract
Sub-Saharan Africa bears the greatest burden of the global Human Immunodeficiency Virus (HIV) epidemic.
Uganda is no exception, with over 1.5 million persons with HIV (PWH), comprising 5.8% of the population.
Improved access to antiretroviral therapy (ART) has transformed HIV from a fatal condition to a chronic disease with long-term survival approaching that of uninfected individuals.
In this setting, increased morbidity and non-AIDS mortality arising from non-communicable disease co-morbidities is a growing challenge in the care of patients with HIV.
Rheumatic and musculoskeletal diseases (RMDs) encompass a broad group of conditions commonly affecting the muscles, bones or joints.
Collectively, these disorders are the leading cause of years of life lived with disability and the fifth highest driver of disability-adjusted life years globally.
In Sub-Saharan Africa, the burden of RMDs is growing due to changing demographic patterns against a backdrop of resource limitation.
The interplay of RMDs and HIV remains a challenge: interactions between the two are diverse and relatively poorly understood, creating barriers to management, and leading to negative health outcomes.
Written in response to “HIV-associated non-communicable diseases research at low- and middle-income country institutions (PAR-23-191)”, this proposal aims to establish a novel registry of patients with HIV and RMDs, which will provide a unique platform for epidemiological and clinical studies of patients with co-morbid HIV and RMD.
Building upon the expertise of the study PIs in HIV, RA and osteoporosis, we further propose a demonstration project focused on patients with co-existing HIV and RA to illustrate the feasibility of this platform to support innovative hypothesis-driven research.
The two independent but related aims will leverage a new patient registry at the Rheumatology Clinic at Mulago National Hospital, a well-established HIV clinic at the same hospital, a rich history of collaboration between Makerere University College of Health Sciences and Yale University School of Medicine, an outstanding advisory committee, and the infrastructure and network of the Uganda Initiative for NCDs.
Taken together, the proposed project has significant public health importance.
It will provide the prerequisite data, training, and infrastructure needed to advance research on RMD burden among PWH.
Creation of this unique research and training platform will foster critical local capacity and an integrated network in Uganda for future prospective studies investigating this important but previously under-recognized problem.
This will build the foundation for future longitudinal studies to assess the burden, biology, spectrum, and the progression of RMDs in HIV.
Sub-Saharan Africa bears the greatest burden of the global Human Immunodeficiency Virus (HIV) epidemic.
Uganda is no exception, with over 1.5 million persons with HIV (PWH), comprising 5.8% of the population.
Improved access to antiretroviral therapy (ART) has transformed HIV from a fatal condition to a chronic disease with long-term survival approaching that of uninfected individuals.
In this setting, increased morbidity and non-AIDS mortality arising from non-communicable disease co-morbidities is a growing challenge in the care of patients with HIV.
Rheumatic and musculoskeletal diseases (RMDs) encompass a broad group of conditions commonly affecting the muscles, bones or joints.
Collectively, these disorders are the leading cause of years of life lived with disability and the fifth highest driver of disability-adjusted life years globally.
In Sub-Saharan Africa, the burden of RMDs is growing due to changing demographic patterns against a backdrop of resource limitation.
The interplay of RMDs and HIV remains a challenge: interactions between the two are diverse and relatively poorly understood, creating barriers to management, and leading to negative health outcomes.
Written in response to “HIV-associated non-communicable diseases research at low- and middle-income country institutions (PAR-23-191)”, this proposal aims to establish a novel registry of patients with HIV and RMDs, which will provide a unique platform for epidemiological and clinical studies of patients with co-morbid HIV and RMD.
Building upon the expertise of the study PIs in HIV, RA and osteoporosis, we further propose a demonstration project focused on patients with co-existing HIV and RA to illustrate the feasibility of this platform to support innovative hypothesis-driven research.
The two independent but related aims will leverage a new patient registry at the Rheumatology Clinic at Mulago National Hospital, a well-established HIV clinic at the same hospital, a rich history of collaboration between Makerere University College of Health Sciences and Yale University School of Medicine, an outstanding advisory committee, and the infrastructure and network of the Uganda Initiative for NCDs.
Taken together, the proposed project has significant public health importance.
It will provide the prerequisite data, training, and infrastructure needed to advance research on RMD burden among PWH.
Creation of this unique research and training platform will foster critical local capacity and an integrated network in Uganda for future prospective studies investigating this important but previously under-recognized problem.
This will build the foundation for future longitudinal studies to assess the burden, biology, spectrum, and the progression of RMDs in HIV.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Uganda
Geographic Scope
Foreign
Related Opportunity
Analysis Notes
Amendment Since initial award the End Date has been extended from 06/30/26 to 06/30/27 and the total obligations have increased 107% from $174,753 to $361,922.
Makerere University College Of Health Sciences was awarded
Uganda HIV & Rheumatic Disease Research Platform
Project Grant R21TW012889
worth $361,922
from Fogarty International Center in August 2024 with work to be completed primarily in Uganda.
The grant
has a duration of 2 years 10 months and
was awarded through assistance program 93.989 International Research and Research Training.
The Project Grant was awarded through grant opportunity Change of Recipient Organization (Type 7 Parent Clinical Trial Optional).
Status
(Ongoing)
Last Modified 5/21/26
Period of Performance
8/19/24
Start Date
6/30/27
End Date
Funding Split
$361.9K
Federal Obligation
$0.0
Non-Federal Obligation
$361.9K
Total Obligated
Activity Timeline
Transaction History
Modifications to R21TW012889
Additional Detail
Award ID FAIN
R21TW012889
SAI Number
R21TW012889-4171036233
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NF00 NIH Fogarty International Center
Funding Office
75NF00 NIH Fogarty International Center
Awardee UEI
QSXBGHKN8KV6
Awardee CAGE
STR11
Performance District
Not Applicable
Modified: 5/21/26